Speaker Profile
PMWC LUMINARY AWARD
Pioneered immune tolerance and Treg biology, enabling therapies that delay type 1 diabetes
Ph.D., Distinguished Professor Emeritus of Metabolism and Endocrinology, UCSF
Biography
Dr. Jeff Bluestone is a Distinguished Emeritus Professor in the Diabetes Center at
UCSF and a managing director of Vie Ventures. He served in various other roles over 25
years at UCSF, including as a member of the faculty, Founding Director of the Diabetes Center,
and Executive Vice Chancellor and Provost. He is an international leader in the field of
immunotherapy and has published more than 500 papers focused on understanding the basic
processes that control T-cell activation and immune tolerance in autoimmunity, organ
transplantation and cancer. His research has led to the development of the first FDA-approved
drug that delays/prevents autoimmune Type 1 diabetes and the first FDA-approved checkpoint
inhibitor for the treatment of metastatic melanoma and other cancers. Dr. Bluestone was the
Founding Director of the Immune Tolerance Network and the Founding CEO of the Parker
Institute for Cancer Immunotherapy. Dr. Bluestone is a member of the National Academy of
Science, National Academy of Medicine, and American Academy of Arts and Sciences.
Session Abstract – PMWC 2027 Silicon Valley
Davos of Precision Medicine
PMWC 2027 Program
January 27–29, 2027 · Santa Clara Convention Center
Swipe speakers · Tap a card for sessions →
In a few words.
PMWC is indeed The Davos of Biotech
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
